

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.*



友芝友生物製藥

**Wuhan YZY Biopharma Co., Ltd.**  
**武漢友芝友生物製藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2496)**

**NOTICE OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2024**

**NOTICE IS HEREBY GIVEN THAT** the first extraordinary general meeting of 2024 (the “EGM”) of Wuhan YZY Biopharma Co., Ltd. (武漢友芝友生物製藥股份有限公司) (the “Company”) will be held at 10:00 a.m. on Tuesday, October 22, 2024 at Conference Room 2, 2nd Floor, Building C2-1, No. 666 Gaoxin Road, East Lake High Tech Development Zone, Wuhan, Hubei Province, PRC for the purposes of considering and, if thought fit, passing the following resolutions.

**ORDINARY RESOLUTIONS**

1. To consider and approve the proposed removal of Dr. Guo Hongwei as non-executive Director.
2. To consider and approve the proposed appointment of Mr. Wen Zhicheng as non-executive Director, subject to and conditional upon the passing of the resolution numbered 1 above.

**SPECIAL RESOLUTION**

3. To consider and approve the proposed amendments to the Articles of Association as set out in the circular of the Company dated September 30, 2024 and to authorize the Directors to deal with on behalf of the Company the relevant application(s), approval(s), registration(s), filing(s) and other related procedures or issues and to make further amendment(s) (where necessary) pursuant to the requirements of the relevant governmental and/or regulatory authorities arising therefrom.

By order of the Board  
**Wuhan YZY Biopharma Co., Ltd.**  
**Dr. Zhou Pengfei**

*Chairman of the Board, Executive Director and  
Chief Executive Officer*

Wuhan, PRC, September 30, 2024

*As of the date of this notice, the Board comprises Dr. Zhou Pengfei as executive Director, Dr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu, Ms. Liang Qian, Dr. Guo Hongwei and Mr. Xie Shouwu as non-executive Directors, and Dr. Cheng Bin, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive Directors.*

*Notes:*

1. Details of the above resolutions are set out in the circular of the Company dated September 30, 2024 (the “**Circular**”). Unless the context otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the Circular.
2. The resolutions at the meeting will be taken by poll pursuant to the Listing Rules and the Articles of Association. The results of the poll will be published on the websites of the Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)) and the Company ([www.zybio.com](http://www.zybio.com)) in accordance with the Listing Rules.
3. Any Shareholder entitled to attend and vote at the meeting is entitled to appoint one or more proxies to attend and vote instead of him/her/it. A proxy needs not be a Shareholder. If more than one proxy is appointed, the number of shares in respect of which each such proxy so appointed must be specified in the relevant form of proxy. Every Shareholder present in person or by proxy shall be entitled to one vote for each share held by him/her/it.
4. The form of proxy shall be signed by the Shareholder or his/her/its attorney who has been authorized in writing. If the Shareholder is a corporation, the form of proxy shall be affixed with the corporation’s seal or signed by its director, or its attorney duly authorized in writing. If the form of proxy is signed by the attorney of the Shareholder, the power of attorney or other authorization document shall be notarized. For Shareholders, the aforementioned documents must be deposited at the Company’s H Share Registrar, Computershare Hong Kong Investor Services Limited, at 17M/F, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong not less than 24 hours before the time appointed for the meeting (i.e. not later than 10:00 a.m. on Monday, October 21, 2024) or the adjourned meeting (as the case may be). Completion and return of the form of proxy shall not preclude a Shareholder from attending and voting in person at the meeting and, in such event, the instrument appointing a proxy shall be deemed to be revoked.
5. An individual Shareholder shall produce his/her identification document when attending the EGM.
6. A proxy who attends the EGM upon entrustment by a Shareholder should produce his/her identification document and the power of attorney issued by the Shareholder. If a representative of a corporate Shareholder attends the EGM, such representative shall produce his/her identification document and the notarized copy of the power of attorney or other notarized copy of any authorization documents issued by such corporate Shareholder.
7. In order to determine the rights of H Shareholders to attend and vote at the EGM of the to be held on Tuesday, October 22, 2024, the register of members of H Shares will be closed from Thursday, October 17, 2024 to Tuesday, October 22, 2024 (both days inclusive), during which period no transfer of H Shares will be registered. Members whose names appear on the register of members of the Company on Tuesday, October 22, 2024 will be entitled to attend and vote at the EGM. In order to be eligible for attending the EGM, all completed transfer forms accomplished by the relevant share certificates must be lodged with the Company’s share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong, for registration not later than 4:30 p.m. on Wednesday, October 16, 2024.
8. The contact of the Company:  
  
Address: Board Office  
Wuhan YZY Biopharma Co., Ltd. (武漢友芝友生物製藥股份有限公司)  
No. 666 Gaoxin Road  
East Lake High Tech Development Zone  
Wuhan, Hubei Province  
PRC  
Postal Code: 430075  
Tel: (86) 027-82668988  
Contact Person: Mr. Zheng Jianhua  
Email: zhengjianhua@zybio.com
9. References to time and dates in this notice are to Hong Kong time and dates.